insights_auto
Why is ASND down 5.32%?
Dive Deeperchevron_right
ASND:NASDAQ
Ascendis Pharma A/S
$255.96
arrow_downward
-5.32%(-14.37) 1D
$255.96
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 19, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ASND...
Open
$269.76
High
$271.45
Low
$254.03
Mkt. cap
17.00B
Avg. vol.
704.68K
Volume
970.44K
P/E ratio
17.79
52-wk high
$282.15
52-wk low
$188.08
EPS
$14.39
Shares outstanding
66.40M
No. of employees
1K
Open
$269.76
High
$271.45
Low
$254.03
Mkt. cap
17.00B
Avg. vol.
704.68K
Volume
970.44K
P/E ratio
17.79
52-wk high
$282.15
52-wk low
$188.08
EPS
$14.39
Shares outstanding
66.40M
No. of employees
1K
News stories
From web sources and news partners
TradingView
·
2 days ago
ASND: Three marketed products underpin €5B revenue ambition by 2030 and €10B by 2035
Investing.com
·
2 days ago
Ascendis Pharma at Jefferies Global Healthcare Conference: growth plan widens
About Ascendis Pharma A/S
CEO-
Employees1.19K
Founded2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteascendispharma.com
Analyst ratings
Based on 20 analysts giving stock ratings to ASND in the past 3 months
Strong buy
Buy
19
Hold
1
Sell
0
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for ASND in the last 3 months.
Highest
Current $255.96
$356.00 (+39.08%)
Average
$320.00 (+25.02%)
Lowest
$274.00 (+7.05%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Eric Joseph Citi | Buy | Maintained | $335.00 | +30.9% | 11/16/2026 |
Eliana Merle Barclays | Buy | Maintained | $341.00 | +33.2% | 11/16/2026 |
Luca Issi RBC Capital | Buy | Maintained | $290.00 | +13.3% | 11/12/2026 |
Joseph Schwartz Leerink Partners | Buy | Reiterated | $326.00 | +27.4% | 11/13/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | $304.00 | +18.8% | 11/12/2026 |
Maxwell Skor Morgan Stanley | Buy | Maintained | $302.00 | +18% | 11/13/2026 |
Yun Zhong Wedbush | Buy | Reiterated | $346.00 | +35.2% | 11/13/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $356.00 | +39.1% | 11/13/2026 |
Derek Archila Wells Fargo | Buy | Reiterated | $330.00 | +28.9% | 11/13/2026 |
Joon Lee UBS | Buy | Reiterated | $315.00 | +23.1% | 11/13/2026 |
Gary Nachman Canaccord Genuity | Hold | Maintained | $274.00 | +7% | 11/13/2026 |
Mitchell Kapoor H.C. Wainwright | Buy | Reiterated | $335.00 | +30.9% | 11/13/2026 |
Yaron Werber TD Cowen | Buy | Reiterated | $352.00 | +37.5% | 11/13/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $273.00 | +6.7% | 11/02/2026 |
Jessica Fye J.P. Morgan | Buy | Reiterated | - | - | 10/10/2026 |
Li Watsek Cantor Fitzgerald | Buy | Maintained | $300.00 | +17.2% | 09/25/2026 |
David Lebowitz BMO Capital | Buy | Maintained | $319.00 | +24.6% | 09/14/2026 |
Martin Auster Raymond James | Buy | Maintained | $287.00 | +12.1% | 09/15/2026 |
Leland Gershell Oppenheimer | Buy | Maintained | $312.00 | +21.9% | 09/02/2026 |
Alex Thompson CFA Stifel Nicolaus | Buy | Maintained | $326.00 | +27.4% | 09/01/2026 |
Unknown Analyst Oppenheimer | Buy | Maintained | $312.00 | +21.9% | 09/02/2026 |
Faisal Khurshid Jefferies | Buy | Maintained | $330.00 | +28.9% | 08/31/2026 |
Evan Seigerman BMO Capital | Buy | Initiated | $319.00 | +24.6% | 08/18/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $319.00 | +24.6% | 08/18/2026 |
Paul Choi Goldman Sachs | Buy | Maintained | $300.00 | +17.2% | 07/27/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $295.00 | +15.3% | 05/20/2026 |
Unknown Analyst Citi | Buy | Initiated | $355.00 | +38.7% | 05/15/2026 |
Unknown Analyst Evercore ISI | Buy | Maintained | $324.00 | +26.6% | 04/13/2026 |
Last report
Nov 12, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
€1.71 / €1.15
+48.70%beat
arrow_upward
Revenue / Est. (EUR)
369.66M / 366.36M
+0.90%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 247.50M | 246.60M | 339.28M | 369.66M |
Cost of goods sold | 23.60M | 17.52M | 27.66M | 28.31M |
Cost of revenue | 23.60M | 17.52M | 27.66M | 28.31M |
Research and development expenses | 82.20M | 59.04M | 75.89M | 69.92M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 139.31M | 145.23M | 173.34M | 146.84M |
Operating expense | 221.51M | 204.27M | 91.16M | 216.77M |
Total operating expenses | 245.11M | 221.79M | 118.82M | 245.08M |
Operating income | 2.39M | 24.81M | 220.46M | 124.58M |
Other non operating income | -105.57M | - | - | - |
EBT including unusual items | -26.70M | -48.18M | 230.09M | 113.37M |
EBT excluding unusual items | -34.21M | -48.18M | 230.09M | 113.37M |
Income tax expense | 6.86M | -677.52M | 23.12M | 39.40M |
Effective tax rate | -25.68% | 1,406.31% | 10.05% | 34.75% |
Other operating expenses | - | - | -158.07M | - |
Net income | -33.56M | 629.34M | 206.97M | 73.97M |
Net profit margin | -13.56% | 255.21% | 61.00% | 20.01% |
Earnings per share | -0.55 | 0.27 | 0.90 | 1.71 |
Interest and investment income | 64.06M | 4.52M | 19.96M | 7.71M |
Interest expense | -74.65M | -67.26M | -14.17M | -12.04M |
Net interest expenses | -10.59M | -62.74M | 5.79M | -4.34M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 3.60M | 29.03M | 225.03M | 129.22M |
Gain or loss from assets sale | - | - | 21.00K | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events